GCIG
GILD icon

Grand Central Investment Group’s Gilead Sciences GILD Stock Holding History

Grand Central Investment Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Sell
15,261
-172
-1% -$22.7K 1.61% 24
2026
Q1 		$2.15M Hold
15,433
– – 1.59% 23
2025
Q4 		$1.89M Buy
+15,433
New +$1.88M 1.37% 21

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Grand Central Investment Group's GILD Position: Q2 2026 in Review

Grand Central Investment Group reduced its Gilead Sciences (GILD) stake by 1.1% in Q2 2026, selling an estimated $22.7K and leaving 15,261 shares worth $1.93M. The position accounts for 1.61% of the portfolio, ranked #24.

Grand Central Investment Group first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.15M in Q1 2026. 2,283 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Grand Central Investment Group held 15,261 shares of Gilead Sciences worth $1.93M as of Q2 2026.
  • Grand Central Investment Group sold 172 Gilead Sciences shares in Q2 2026, an estimated $22.7K.
  • Gilead Sciences made up 1.61% of Grand Central Investment Group's portfolio in Q2 2026, its #24 holding.
  • Grand Central Investment Group first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Grand Central Investment Group's Gilead Sciences position peaked at $2.15M in Q1 2026.
  • 2,283 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Grand Central Investment Group's 13F filing for Q2 2026, filed 4 Aug 2026.